ǰÑÔ
¼××´ÏÙ¹¦Ð§¿º½øÖ¢(hyperthyroidism)£¬¼ò³Æ¼×¿ºÖ¢£¬ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔÓÉʹ¼××´ÏÙÏÙÌåÉøÍ¸¹ý¶à¼××´ÏÙ¼¤ËØ£¬µ¼ÖÂÒÔÑ»·¡¢Éñ¾¡¢Ïû»¯µÈϵͳÐË·ÜÐÔÔö¸ßºÍ´úл¿º½øÎªÖ÷ÒªÁÙ´²ÌåÏÖµÄÒ»ÖÖÈ«ÉíÐÔ¼²²¡£¬ÌåÏÖΪÃÖÂþÐÔ¼××´ÏÙÖס¢Í»ÑÛÕ÷¡¢Ð͝¹ýËÙ¡¢¶àʳ¡¢ÏûÊÝ¡¢¶àº¹¡¢Î·ÈÈ¡¢Ò×¼¤¶¯¡£ÒýÆð¼×¿ºÖ¢µÄ²¡ÒòÖ÷ÒªÓУº¢Ù×ÔÉíÃâÒßÐÔ¼²²¡£¬È磬ÃÖÂýÐÔ¶¾ÐÔ¼××´ÏÙÖ×(Graves disease,GD)£¬×ÔÉíÌåÄÚ±¬·¢¿¹¼××´ÏÙÊÜÌå(thyroid stimulating hormone receptor,TSHR)¿¹Ì壬´Ë¿¹ÌåÓë¼××´ÏÙTSHRÍŽᣬһÁ¬Ð˷ܼ××´ÏÙ£¬µ¼ÖÂÌ«¹ýºÏ³ÉºÍÉøÍ¸T3ºÍT4¡£GDÕ¼ËùÓм׿ºÖ¢µÄ80%¡«85%¡£¢ÚTSHR»ùÒòÍ»±ä£¬µ¼ÖÂÌåÖÊÐÔÊÜÌ弤»î£¬Ò»Á¬Ð˷ܼ××´ÏٺϳɺÍÊͷŹýÁ¿¼××´ÏÙ¼¤ËØ¡£ÕâÒ»¼²²¡¾ßÓÐÒÅ´«ÐÔ£¬Îª¼Ò×åÐÔ³£È¾É«ÌåÏÔÐԼ׿º×ÛºÏÕ÷£¬·ºÆðÔÚÓ¤¶ùÆÚ¡£¢ÛÔÚ¶àÄê¶à½á½ÚÐÔ¶¾ÐÔ¼××´ÏÙÖ׵Ļù´¡Éϱ¬·¢¼×¿ºÖ¢×´¡£
Õë¶ÔÉÏÊö²¡Òò£¬¼×¿ºÖ¢¶¯ÎïÄ£×ÓÖÆ×÷¿É·ÖΪÓÕ·¢ÐÔ¶¯ÎïÄ£×ÓºÍת»ùÒò¶¯ÎïÄ£×Ó2Àà¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó¡¢Ð¡Êó¡¢¼ÒÍÃ
¡¾ÔìÄ£»úÖÆ¡¿£º
ͨ¹ý¿Ú·þ»ò×¢Éä¼××´ÏÙËØ£¬ÈËΪÔöÌí¶¯ÎïÌåÄÚ¼××´ÏÙËØº¬Á¿£¬´Ó¶øÊ¹¶¯ÎïÌåÏÖ³ö¼×¿ºÖ¢µÄÖÖÖÖÖ¢×´¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
1.СÊó À¥Ã÷СÊó£¬ÌåÖØ18~20g£¬Óü××´ÏÙÆ¬»ìÐüÒº320mg/kg¹à裬һÁ¬¹àθ9Ìì¡£
2.´óÊó ³ÉÄê´óÊó£¬ÌåÖØ180~220g£¬Óü××´ÏÙÆ¬»ìÐüÒº40mg/d¹à裬һÁ¬7Ìì¡£»òÓÃ×ó¼××´ÏÙËØÄÆ1mg/(kg·d)ÌåÖØ¹à裬һÁ¬10Ìì¡£
3.¼ÒÍà ÐÂÎ÷À¼Íã¬ÌåÖØ2.0~2.5kg£¬ÓÃ×ó¼××´ÏÙËØÄÆ0.5mg/(kg·d)ƤÏÂ×¢Éä12~14Ìì¡£
ÖÖÖÖ¶¯ÎïÔìÄ£ºó£¬¿É¾ÙÐÐÉãʳÁ¿¡¢ÒûË®Á¿¡¢ÌåΡ¢ÐĵçͼÒÔ¼°ÑªÇåT3¡¢T4º¬Á¿²â¶¨¡£
¡¾Ä£×ÓÌØµã¡¿£º
¸øÓèÍâÔ´ÐÔ¼××´ÏÙËØºó£¬¶¯Îï¿É·ºÆðÉãʳÁ¿¡¢ÒûË®Á¿ÔöÌí£¬ÌåÎÂÉý¸ß£¬ÐÄÂÊÔö¿ì£¬ÑªÇåT3¡¢T4º¬Á¿ÉÏÉý¡£ÍõÄÐÄÔà·Ê´ó¡¢Ëõ¶ÌѹÔö¸ß£¬Ñª½¬ÐÄ·¿ÀûÄÆëÄ(atrial natriuretic peptide)ÉøÍ¸ÔöÌí¡£ÕâЩÁÙ´²ÌåÏÖ¾ùÓëÈ˵ļ׿ºÖ¢×´ºÜÊÇÏàËÆ¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
ÍâÔ´ÐÔ¼××´ÏÙËØÔö²¹·¨ÓÕ·¢¼×¿ºÖ¢Ä£×ÓÊÊÓÃÓÚ¼××´ÏÙËØ¹ý¶à¶Ô»úÌåµÄÉúÎïѧЧӦÑо¿ÒÔ¼°¿¹¼×¿ºÒ©ÎïµÄɸѡºÍҩЧѧÑо¿¡£±¾Ä£×ÓÊÇÖ±½Ó½«ÍâÔ´ÐÔ¼××´ÏÙËØ¸øÓ趯ÎÔì³É¶¯ÎïÌåÄÚ¼××´ÏÙËØË®Æ½¹ý¸ß¶øµ¼ÖÂһϵÁеÄÁÙ´²ÌåÏÖ¡£Òò´Ë£¬¸øÒ©¼ÁÁ¿ÓëÄ£×ÓµÄÀàÐͺÍÔìģʱ¼äÓÐÇ×½ü¹ØÏµ¡£¸øÒ©¼ÁÁ¿¹ý¸ß£¬Ôìģʱ¼äËõ¶Ì£¬µ«¿ÉÄÜéæÃüÂÊÉý¸ß¡£¿ÉÊÇÍâÔ´ÐÔ¼××´ÏÙËØµÄÔöÌí·´ÏìÐÔÒÖÖÆ´¹ÌåµÄ´Ù¼××´ÏÙËØ(TSH)µÄÉøÍ¸£¬ÒÖÖÆ¼××´ÏÙÏÙÌåÉøÍ¸£¬ÕâÓë¼×¿ºÖ¢µÄ·¢²¡»úÀíºÍ¼××´ÏÙ²¡Àí¸Ä±ä²»ÏàÇкϡ£´Ë¾ÞϸÊóÄ£×Ó¿ÉÓü××´ÏÙËØÉúÎïѧЧӦÑо¿ºÍÒ»Ñùƽ³£ÖÎÁƼ׿ºÖ¢Ò©ÎïµÄҩЧѧÑо¿¡£
ÍÃÊǼ××´ÏÙ¼¤ËصÄÒ׸ж¯ÎÓÃÍÃÍâÔ´ÐÔ¼××´ÏÙËØ½¨ÉèµÄ¼×¿ºÐÔ¸ßѪѹѪѹÎȹ̣¬ÇÒÔڼ׿ºÐÔ¸ßѪѹģ×ÓÔìÄ£Àú³ÌÖÐÐÄÂÊ¡¢Ëõ¶ÌѹºÍѪ½¬ANPˮƽÓëÐÄÔàÖÊÁ¿Ö¸Êý³ÊÕýÏà¹Ø¡£
²Î¿¼ÎÄÏ×£º
1.ÎäÃô£¬Ê©±üÒø£®Graves²¡¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®ÉÂÎ÷ҽѧÔÓÖ¾£¬2006, 35 (3):321-323
2.ÕÔ×ÏÇÙ£¬ÀîÀ¼Ó¢£¬ÖìÔÆ¾ê£®hTSHR188-403bp»ùÒòÃâÒßBALB/cСÊó½¨ÉèGraves²¡¶¯ÎïÄ£×Ó£®ÖйúÃâÒßѧÔÓÖ¾£¬2008,24 (2):153-156
3.¼ÖÎýÁ«£¬ÀîÅæÁØ£¬ÐÜÏæÃ÷£¬µÈ£®Ïûñ¨¿ÅÁ£¼Á¶Ô¼××´ÏÙ¹¦Ð§¿º½øÖ¢Ä£×Ó´óÊóÐÄÂÊ¡¢¸ØÎ¼°ÑªÇåT3¡¢T4µÄÓ°Ï죮 ºÓ±±ÖÐÒ½£¬2002,24 (8):632-635
4.´Þçø£¬´úÓÀϼ£¬Õűö£®¼×¿ºÐÍÒõÐéÄ£×ÓСÊó½¹ÂÇÐÐΪµÄÊӲ죮ÖÐÒ©Ò©ÀíÓëÁÙ´²£¬2008,24 (5):78-80
5.Costagliola S, Many MC, Denef JF, et al. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves'disease.J Clin Invest2000, 105(6):803-811
6.Kim-Saijo M,Akamizu T,Ikula K,el al. Generation of a transgenic animal model of hyperthyroid Graves'disease. Eur J Imrnunol, 2003, 33 (9):2531-2538
7.Nagayama Y, Kita-Furuyama M, Ando T, el al. A novel murine model of Graves'hyperthyroidism with intramuscular injection of adeoovirus expressing the thyrotropin receptor. J Immunol, 2002, 168 (6):2789-2794
8.Shimojo N, Kohno Y, Yamaguchi K, el al.Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class ¢ò molecule. Proc Natl Acad Sci U S A, 1996, 93 (20):11074-11079